University of Pennsylvania via Microbe World / Flickr
One biotech startup is hitting 2017 with a running start.
Cancer drug developer Jounce Therapeutics filed for an initial public offering on Dec. 30.
The filing includes a target of $75 million in the public offering, though that’s a placeholder and likely to change.
The filing is coming off a busy year for Jounce. In July, biotech company Celgene invested $261 million in Jounce in a deal that could ultimately be worth as much as $2.5 billion.
Jounce is developing drugs that harness the immune system to better attack cancer cells, a treatment often referred to…